Application of the Nivolumab in the treatment of advanced non-small cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2019.05.009

Abstract

Abstract: Lung cancer has the highest morbidity and mortality among malignant tumors in our country. The treatment researches related to nonsmall cell lung cancer (NSCLC) such as targeted therapy and immunotherapy are the research hotspots in recent years. Nivolumab is the first programmed death-1 (PD-1) inhibitor which is allowed to enter clinical trials, and it is also the first approved drug for tumor immunotherapy in China. In June 2018, Nivolumab injection was marketed in China, and it was used in the secondline treatment for the patients with advanced NSCLC, opened up a new era of the lung cancer treatment in our country. Review the clinical research related to the Nivolumab and NSCLC, summarizing usage, dosage, adverse reactions, will provide a help for clinical application, bring more benefits for patients at the same time.

Key words: Carcinoma, non-small-cell lung, Immunotherapy, Nivolumab

Liu Dongqi, Chen Runze, Liu Yuhan, Zhou huan. Application of the Nivolumab in the treatment of advanced non-small cell lung cancer[J]. Journal of International Oncology, 2019, 46(5): 295-298.

References

［1］ Lim JS, Soo RA. Nivolumab in the treatment of metastatic squamous nonsmall cell lung cancer: a review of the evidence［J］. Ther Adv Respir Dis, 2016, 10(5): 444-454. DOI: 10.1177/1753465816661091. ［2］ Brayer J, Fishman M. Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment［J］. J Immunother, 2014, 37(3): 187-191. DOI: 10.1097/CJI.0000000000000024. ［3］ Hwang YY, Khong PL, Kwong YL. Lowdose nivolumab induced remission in refractory classical Hodgkin lymphoma［J］. Ann Hematol, 2017, 96(7): 1219-1220. DOI: 10.1007/s00277-017-3007-9. ［4］ El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial［J］. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2. ［5］ Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates［J］. Cancer Immunol Res, 2014, 2(9): 846-856. DOI: 10.1158/2326-6066. ［6］ Gettinger S, Horn L, Jackman D, et al. Five-year followup of nivolumab in previously treated advanced non-small cell lung cancer: results from the CA209-033 study［J］. J Clin Oncol, 2018, 36(17): 1675-1684. DOI: 10.1200/JCO.2017.77.0412. ［7］ Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer［J］. N Engl J Med, 2015, 373(2): 123-135. DOI: 10.1056/NEJMoa1504627. ［8］ Borghaei H, PazAres I, Horn I, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer［J］. N Engl J Med, 2015, 373(17): 1627-1639. DOI: 10.1056/NEJMoa1507643. ［9］ Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced nonsmallcell lung cancer: twoyear outcomes from two randomized, openlabel, phase Ⅲ trials (CheckMate 017 and CheckMate 057)［J］. J Clin Oncol, 2017, 35(35): 3924-3933. DOI: 10.1200/JCO.2017.74.3062. ［10］ Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced nonsmallcell lung cancer (CheckMate 017 and CheckMate 057): 3-year up date and outcomes in patients with liver metastases［J］. Ann Oncol, 2018, 29(4): 959-965. DOI: 10.1093/annonc/mdy041. ［11］ Lu S. Nivolumab (nivo) vs Docetaxel (doce) in Chinese patients (pts) with previously treated advanced (adv) nonsmallcell lung cancer (NSCLC): results of CheckMate078［R］. CSCO 2018. ［12］ Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an antiPD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous nonsmallcell lung cancer (CheckMate 063): a phase 2, singlearm trial［J］. Lancet Oncol, 2015, 16(3): 257-265. DOI: 10.1016/S1470-2045(15)70054-9. ［13］ Spigel DR, Mcleod M, Hussein MA, et al. 1297ORandomized results of fixedduration (1-yr) vs continuous nivolumab in patients (pts) with advanced nonsmall cell lung cancer(NSCLC)［J］. Ann Oncol, 2017, 28(Suppl_5). DOI: 10.1093/annonc/mdx380.002. ［14］ Carbone DP, Reck M, PazAres L, et al. FirstLine nivolumab in stage IV or recurrent non-small-cell lung cancer［J］. N Engl J Med, 2017, 376(25): 2415-2426. DOI: 10.1056/NEJMoa1613493. ［15］ Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as firstline treatment for advanced nonsmallcell lung cancer (CheckMate012): results of an openlabel, phase 1, multicohort study［J］. Lancet Oncol, 2017, 18(1): 31-34. DOI: 10.1016/S1470-2045(16)30624-6. ［16］ Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden［J］. N Engl J Med, 2018, 378(22): 2093-2104. DOI: 10.1056/NEJMoa1801946. ［17］ Ready N, Hellmann MD, Awad MM, et al. Firstline nivolumab plus ipilimumab in advanced nonsmallcell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers［J］. J Clin Oncol, 2019, 37(12): 992-1000. DOI: 10.1200/JCO.18.01042. ［18］ Gordon R, Kasler MK, Stasi K, et al. Checkpoint inhibitors: common immunerelated adverse events and their management［J］. Clin J Oncol Nurs, 2017, 21(2): 45-52. DOI: 10.1188/17.CJON.S2.45-52. ［19］ Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature［J］. Cancer, 2018, 124(2): 271-277. DOI: 10.1002/cncr.31043. ［20］ Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of antiPD-1 antibody in cancer［J］. N Engl J Med, 2012, 366(26): 2443-2454. DOI: 10.1056/NEJMoa1200690. ［21］ Waterhouse D, Horn L, Reynolds C, et al. Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153［J］. Cancer Chemother Pharmacol, 2018, 81(4): 679-686. DOI: 10.1007/s00280-018-3527-6.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[6]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[7]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[8]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[9]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[10]	Guo Ciliang, Jiang Chunping, Wu Junhua. Gut microbiome and tumor immunotherapy [J]. Journal of International Oncology, 2023, 50(7): 432-436.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[13]	Gu Anqin, Long Jinhua, Jin Feng. Clinical research progress of immunotherapy for nasopharyngeal carcinoma [J]. Journal of International Oncology, 2023, 50(5): 299-303.
[14]	Ding Hao, Ying Jintao, Fu Maoyong. Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(4): 231-235.
[15]	Ma Pengcheng, Chen Yu. Research progress of primary pulmonary lymphoepithelioma-like carcinoma [J]. Journal of International Oncology, 2023, 50(3): 174-178.